Security Snapshot

Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX) Institutional Ownership

CUSIP: 34962G208

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

1

Shares (Excl. Options)

3

Price

$77.00

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-15,083,932
Value change
-$326,095,587
Number of holders
1
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
20,402,903
SEC-reported price per share
$77.00
Insider filing price
$77.00
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • FBRX - Forte Biosciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 34962G208.
  • 1 institution reported positions in Q3 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 86 to 1 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $432.73MFull value: $432,731,103 · USD · 30 Jun 2026
    to $231.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 1 institution filings for Q3 2026.

Open SEC evidence

Security key

34962G208

13F reference period

Q3 2026

13F holders

1

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
FBRX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 5.9% $25,598,430 1,204,632 BlackRock, Inc. 30 Jun 2026
ALGER ASSOCIATES INC 4.6% -56% $41,274,878 +$13,731,379 935,514 +50% Alger Associates, Inc. 31 Jul 2026
Point72 Asset Management, L.P. 6.3% $21,132,810 792,976 Point72 Asset Management, L.P. 12 Jan 2026
Adage Capital Management, L.P. 3.4% $30,884,000 700,000 Adage Capital Management, L.P. 30 Jun 2026
MILLENNIUM MANAGEMENT LLC 3.2% -40% $12,147,389 -$7,545,465 655,199 -38% Millennium Management LLC 30 Jun 2026
Ikarian Capital, LLC 5% -45% $6,516,387 +$89,063 617,667 +1.4% Ikarian Capital, LLC 30 Jun 2025
Janus Henderson Group Ltd. 2.5% -75% $22,987,226 -$38,215,067 521,016 -62% JANUS HENDERSON GROUP Ltd. 31 Jul 2026
Oliveira Steven Michael 2.4% -62% $6,797,265 -$2,993,786 300,100 -31% Oliveira Steven Michael 08 Jan 2026
PERCEPTIVE ADVISORS LLC 2.5% $1,209,840 163,935 Perceptive Advisors LLC 31 Dec 2024
BIOTECHNOLOGY VALUE FUND L P 0.5% -95% $980,250 -$8,674,080 65,350 -90% BVF PARTNERS L P/IL 30 Sep 2025
BOOTHBAY FUND MANAGEMENT, LLC 0.8% -87% $567,495 -$369,187 53,791 -39% Boothbay Fund Management, LLC 30 Jun 2025
As of 30 Sep 2026, 1 institutional investors reported holding 3 shares of Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX). This represents 0% of the company’s total
20.4MFull value: 20,402,903 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 3 $231 -$326,095,587 $77.00 1
2026 Q2 20,362,673 $432,731,103 +$139,183,257 $21.25 86
2026 Q1 13,521,022 $350,237,410 +$50,671,169 $25.90 68
2025 Q4 11,522,905 $314,510,108 +$55,513,195 $27.27 59
2025 Q3 10,343,866 $155,080,846 +$6,727,909 $15.00 42
2025 Q2 9,809,779 $127,063,335 +$62,289,077 $12.93 33
2025 Q1 5,034,489 $39,316,245 +$4,704,465 $7.76 29
2024 Q4 4,275,821 $97,104,372 +$81,936,549 $22.71 26
2024 Q3 736,630 $4,120,236 +$4,082,162 $5.59 23
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .